In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). Yesterday, analyst Matt Bottomley gave a Buy rating to APH and set a C$24.50 price target.
According to TipRanks.com, Bottomley is ranked #268 out of 4843 analysts.
Read also: SenesTech (SNES) Stock Fires on All Cylinders
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aphria Inc with a C$23.25 average price target.
Based on Aphria Inc’s latest earnings release for the quarter ending February 28, the company reported a quarterly net profit of C$12.94 million. In comparison, last year the company had a GAAP net loss of C$2.59 million.
Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
The company’s shares closed on Tuesday at C$10.42.
